晚期小细胞肺癌患者EGFR-TKI耐药后化疗方案选择及疗效分析

Chemotherapy Choice and Efficacy Analysis in Patients with Advanced NSCLC after EGFR-TKI Resistance

目的:探讨晚期非小细胞肺癌(NSCLC)经EGFR-TKI治疗耐药后化疗的方案选择及其疗效分析。方法:收集EGFR-TKIs获得性耐药后经ARMS检测T790M阴性的晚期NSCLC患者37例,执行TC方案化疗,分析化疗方案的影响因素及治疗效果。结果:获得性耐药后临床模式体现为快速进展型的患者接受TC方案后DCR高于缓慢进展型患者,差异有统计学意义(P<0.05),同时其中位PFS也长于后者,但二组总生存期未见统计学差异。结论:出现EGFR-TKIs获得性耐药后检测为T790M阴性的晚期NSCLC患者,临床模式表现为快速进展型时,选择TC方案化疗较具优势。

Objective To choice and investigate the therapeutic effect of subsequent chemotherapy in patients with advanced NSCLC after EGFR-TKI resistance.Method TC chemotherapy regimens were analyzed about effecacy and influence factor in 37 patients with advanced NSCLC who with T790M-and acquired EGFR-TKI resistance.Results The control rate(DCR)of patients whose clinical manifestation developed rapidly was significangly higher than that of patients whose clinical manifestation developed slowly after receiving TC chemotherapy regimen(P<0.05),In the meanwhile the median PFS of patients of the former was longer than the latter,but there was not statistical significance in OS between the two groups.Conclusion For T790M-patients with advanced NSCLC who acquired EGFR-TKI resistance and clinical manifestation developing rapidly,TC chemotherapy regimen could be more beneficial.